Showing results (481-490 of 782) with videos related to
Sort By:
Pageof 79
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2013
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growthEmanuela Leone, Eugenio Morelli, Maria T Di Martino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak, Don M Benson, William Bensinger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2009
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemiaHai T Ngo, Abdel Kareem Azab, Mena Farag, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemiaSteven P Treon, Mark Hansen, Andrew R Branagan, et al.Blood Cancer Discovery|June 28, 2021
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcareNicole Gormley, Lola Fashoyin-Aje, Trevan Locke, et al.Molecular Cancer Therapeutics|June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.British Journal of Haematology|September 12, 2008
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myelomaSundar Jagannath, Bart Barlogie, James R Berenson, et al.Cells|November 30, 2019
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with IsatuximabThomas G Martin, Kathryn Corzo, Marielle Chiron, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.Blood|October 25, 2008
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKYutaka Okawa, Teru Hideshima, Paul Steed, et al.Pageof 79